IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
Portfolio Pulse from
IN8bio announced continued progression-free survival in its Phase 1 trial of INB-100 allogeneic gamma-delta T cells for leukemias, presented at the 2024 American Society of Hematology Annual Meeting.
December 10, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's Phase 1 trial of INB-100 shows continued progression-free survival, indicating potential efficacy in leukemia treatment.
The announcement of continued progression-free survival in a Phase 1 trial is a positive indicator of the potential efficacy of IN8bio's INB-100 treatment for leukemias. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100